Revance's crow's feet treatment fails Phase III

Revance Therapeutics Inc. (NASDAQ:RVNC) fell $4.44 (24%) to $13.91 in early after-hours trading Monday after its daxibotulinumtoxinA Topical Gel (RT001) missed the primary endpoints in the Phase III REALISE 1 study to treat severe lateral canthal lines, or crow's feet. The company said it will discontinue the candidate's development for canthal lines and axillary hyperhidrosis.

RT001 failed to improve either of two scores from baseline after 28 days of treatment. The 450-patient REALISE 1 compared the effects of RT001 and placebo on Investigator's Global Assessment of Lateral Canthal Lines (IGA-LCL) and Patient Severity Assessment (PSA) scores. ...